Hemorrhage Countermeasure Evaluation Capabilities RFI
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Defense Advanced Research Projects Agency (DARPA), specifically its Biological Technologies Office (BTO), has issued a Request for Information (RFI) titled "Hemorrhage Countermeasure Evaluation Capabilities". This RFI seeks input from industry and academia on capabilities for providing independent verification and validation, clinical trial support, and commercialization assistance for hemorrhage countermeasures. DARPA is particularly interested in organizations that can offer comprehensive support across all these domains. Responses are due by May 4, 2026, at 4:00 PM ET.
Purpose & Scope
DARPA BTO aims to identify potential partners capable of conducting third-party assessments of the safety and efficacy of hemorrhage countermeasures. The ultimate goal is to facilitate the transition of these products from research and development to civilian and government markets. This RFI is a preliminary step to gather information and does not constitute a solicitation for proposals.
Information Requested
Respondents are requested to submit a white paper detailing their organization's experience, facilities, and technical approach. The white paper should address the following key areas:
- Organizational Capabilities and Past Performance: Core competencies, preclinical and clinical research facilities (including vivarium accreditation), and relevant past performance, especially with government agencies.
- Preclinical Evaluation Capabilities: Technical approach for in vitro and in vivo studies, and Good Laboratory Practice (GLP) capabilities.
- Clinical Trial Support: Experience in designing and managing Phase I and Phase II clinical trials, and expertise in clinical regulatory affairs (IRBs, IND submissions).
- Technology Commercialization and Transition Support: Experience in technical/financial due diligence, commercialization strategies, intellectual property landscapes, and market potential for drugs, biologics, and combination products.
- Program Management and Key Personnel: Expertise of key personnel and a notional 3-year program timeline.
- Rough Order of Magnitude (ROM) Estimate: A ROM estimate for the full scope of capabilities, broken down by major phase, with an estimated budget by year for a notional 5-year effort.
Submission Details
White papers should be concise, limited to 10 pages, use 12-point font, and 1-inch margins. Submissions must be sent electronically in PDF format to DARPA-SN-26-61@darpa.mil. Proprietary information should be clearly identified.
Contract & Timeline
- Type: Special Notice / Request for Information (RFI)
- Set-Aside: None specified
- Response Due: May 4, 2026, 4:00 PM ET
- Published: April 9, 2026
- Agency: Defense Advanced Research Projects Agency (DARPA) / Biological Technologies Office (BTO)
Important Notes
This RFI is for information gathering and planning purposes only. It does not obligate DARPA to issue a solicitation or award a contract. No payment will be made for submitted information, and submission is voluntary. DARPA will not reimburse costs incurred in responding.